Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...

Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Lynnette A. Clinton, who served as vice president of applications in BayCare Health System's information services (IS) department until last December, has returned to the health system as chief ...

A judge dismissed a lawsuit from the Republican National Committee over Michigan's qualified voter list on Tuesday, ruling that the GOP had failed to identify "a plausible ...

The American Society for Preventive Cardiology (ASPC) recently announced that they will be accepting applications for the position of Editor-in-Chief for the American Journal of Preventive Cardiology ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

There is also a vaccine called Abrysvo under the brand name and RSVpreF under the generic name, for pregnant women between 32 ...

Fleet Street legend and Mirror columnist, Paul Routledge, sends gentle tales from his West Yorkshire allotment, Mrs R’s ...